-+ 0.00%
-+ 0.00%
-+ 0.00%

VIR BIOTECHNOLOGY ANNOUNCES PRIMARY ENDPOINT MET IN PIVOTAL PHASE 3 ECLIPSE 1 TRIAL FOR ELEBSIRAN AND TOBEVIBART IN CHRONIC HEPATITIS DELTA

Reuters·11/08/2026 21:15:00

Please log in to view news